Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

492
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
492
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

203
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
203
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

694
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
694
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

514
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
514
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

2.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.4K
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.5K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.5K
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. Ldlコレステロールの上昇と心筋梗塞と動脈硬化性心血管疾患のリスクの上昇,70~100歳の個体:現代の第一予防コホート

LDLコレステロールの上昇と心筋梗塞と動脈硬化性心血管疾患のリスクの上昇,70~100歳の個体:現代の第一予防コホート

Martin Bødtker Mortensen1, Børge Grønne Nordestgaard2

  • 1Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Biochemistry and Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Lancet (London, England)
|November 13, 2020

関連する実験動画

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.6K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.6K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.3K

PubMed で要約を見る

まとめ
この要約は機械生成です。

70歳から100歳までのLDLコレステロールが高い高齢者は,心臓発作や心血管疾患のリスクが高まります. スタチンの治療に必要な人数の減少は,この年齢層において標的型予防が有効であることを示唆しています.

科学分野:

  • 心臓病科
  • 予防医学
  • 高齢者医療

背景:

  • 過去の研究では,LDLコレステロールの高値と70歳以上の患者の心血管疾患リスクとの間に関連がないことが示されました.
  • この研究は,70~100歳の現代人群でこの仮説を検証しています.

研究 の 目的:

  • 70~100歳におけるLDLコレステロール値と心筋梗塞 (MI) と動脈硬化性心血管疾患 (ASCVD) のリスクとの関連を評価する.
  • この集団におけるスタチン治療の潜在的な効果を評価する.

主な方法:

  • コペンハーゲン一般人口研究 (CGPS) の20~100歳の91,131人を対象に,ASCVD,糖尿病,スタチンの使用を未経験で分析した.
  • 標準検査を用いたLDLコレステロールの測定とMIとASCVDのハザード比 (HR) と絶対発生率の計算.
  • 1つのイベントを防ぐために5年間にわたって治療する必要がある数 (NNT) の推定.

主要な成果:

  • 増加したLDLコレステロールは,すべての年齢層,特に70~100歳の年齢層において,心臓発作とASCVDのリスクを有意に増加させた.
  • LDLコレステロール≥5. 0mmol/ Lの80~100歳の患者は,LDL<3. 0mmol/ Lの患者と比較して,心臓発作のリスクがほぼ3倍に増加しました.
  • スタチン療法におけるNNTが最も低い70~100歳のグループで,LDLの1. 0mmol/ L増加あたりのMIとASCVDの絶対リスクが最も高かった.

関連する実験動画

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.6K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.6K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.3K

結論:

  • 過去の発見とは対照的に,現在のデータは,LDLコレステロールの上昇が,70~100歳の個体において,心筋梗塞およびASCVDのリスクの増加と関連していることを示しています.
  • この集団は,スタチン療法による主要な予防の絶対的なリスクと最大の潜在的利益を示しています.
  • 研究結果は,高齢者の心血管疾患の標的型予防戦略を支持しています.